Inogen prelim Q4 rev ~$82M (+2% YoY); FY25 rev ~$349M (+4%); order delays into H1 2026

Inogen Inc

2025-FY EPS reported -$0.86 revenue$348,668,000

Q4 2025 preliminary revenue ~$82M, up ~2% YoY; full-year 2025 ~$349M, up ~4% YoY.
Company expects to achieve positive Adjusted EBITDA for full-year 2025.
Shift in timing of a few large customer orders from Q4 2025 to H1 2026 caused disappointment.
Full-year highlights: launches of Voxi 5 concentrator and Aurora Masks in U.S.; revenue growth and progress toward profitability.
Full Q4/FY2025 results and 2026 guidance to be announced on February 24, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.